One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026;… One-year follow-up data from Phase 2 t...
IDEAYA Biosciences (IDYA) provided a business update including an overview of key corporate objectives for 2026. 2026 Corporate Objectives: Daro… IDEAYA Biosciences (IDYA) provided a business up...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond… HAYWARD, Calif.–(BUSINESS WIR...
The Colossal Foundation, the nonprofit arm of the science fiction-y Dallas startup, announced Wednesday it had secured an additional $50 million in funding, bringing its total purse to $100 million. T...
